# Lumos Pharma

> Lumos Pharma is an Austin-based clinical-stage biopharmaceutical company developing LUM-201, an investigational daily oral growth hormone secretagogue for selected children with pediatric growth hormone deficiency. Acquired by Double Point Ventures in December 2024, it is pursuing a multinational Phase 3 trial that uses biomarkers to identify children likely to respond.

- **Founded:** 2011
- **Headquarters:** Austin, United States
- **Founders:** Richard J. “Rick” Hawkins (Founder; former Chairman and CEO)
- **Products:** LUM-201 (ibutamoren), LUM-201 predictive enrichment marker strategy, LUM-001 (discontinued)
- **Notable:** LUM-201 has orphan drug designation in the US and EU; designation is not approval., Company-reported Phase 2 OraGrowtH210 and OraGrowtH212 topline results met primary and secondary endpoints in 2023., Completed December 2024 acquisition by Double Point Ventures.

## Products & services

- **LUM-201 (ibutamoren)** — Investigational once-daily oral small-molecule growth hormone secretagogue; acquired from Ammonett in 2018 and now in a recruiting Phase 3 trial for selected, treatment-naive prepubertal children with GHD. Not an approved product.
- **LUM-201 predictive enrichment marker strategy** — Investigational screening approach combining baseline IGF-1 and growth hormone response to a single LUM-201 dose to select potential responders.
- **LUM-001 (discontinued)** — Former creatine transporter deficiency candidate. Clinical development voluntarily halted after a nonclinical toxicology signal; program discontinued in 2019.

## Achievements

- LUM-201 has orphan drug designation in the US and EU; designation is not approval.
- Company-reported Phase 2 OraGrowtH210 and OraGrowtH212 topline results met primary and secondary endpoints in 2023.
- Completed December 2024 acquisition by Double Point Ventures.
- Phase 3 NCT06948214 records an actual May 20, 2026 start and recruiting status in the September 2026 update.

## Latest updates

- **2024-12** — Double Point Ventures completed acquisition at USD 4.25 cash per share plus one contingent value right; Lumos ceased Nasdaq trading.
- **2025-10** — Corporate presentation outlined a 150-patient placebo-controlled global Phase 3 trial and continuing extension studies.
- **2026-05** — Phase 3 registry records actual study start on May 20, 2026.
- **2026-09** — ClinicalTrials.gov update lists Phase 3 as recruiting, with estimated 150 participants and estimated primary completion in December 2027.

## Links

- Website: https://lumos-pharma.com/
- LinkedIn: https://www.linkedin.com/company/lumos-pharma/
- Twitter/X: https://twitter.com/lumos_pharma
- Instagram: https://www.instagram.com/lumospharma/
- Facebook: https://www.facebook.com/Lumos-Pharma-1083819218408089/

---

Profile page: https://yespress.io/lumos-pharma
Published by YesPress — https://yespress.io
Last updated: 2026-10-05